Compare FOFO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FOFO | NEUP |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 14.9M |
| IPO Year | 2025 | 2002 |
| Metric | FOFO | NEUP |
|---|---|---|
| Price | $1.76 | $2.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 32.8K |
| Earning Date | 12-04-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,174,165.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.58 | $2.54 |
| 52 Week High | $14.93 | $5.53 |
| Indicator | FOFO | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 16.20 |
| Support Level | $1.76 | N/A |
| Resistance Level | $1.97 | $4.15 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 41.86 | 2.11 |
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.